Results 151 to 160 of about 17,663 (255)

Sleep Apnoea Variability in Pacemaker Patients: A Women‐Predominant Phenotype

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Sex‐specific longitudinal phenotypes of sleep apnoea revealed by night‐to‐night variability. ABSTRACT Study Objectives Single‐night polysomnography assumes stable sleep apnoea (SA) severity; night‐to‐night variability may identify clinically relevant phenotypes, particularly in women. Sex/gender‐specific longitudinal phenotypes were characterised using
Philipp Spitaler, Valentin Bilgeri, Gudrun Feuchtner, Patrick Rockenschaub, Fabian Barbieri, Birkan Tugrul, Agne Adukauskaite, Markus Stühlinger, Bernhard Erich Pfeifer, Sabine Ludwig, Peter Willeit, Axel Bauer, Wolfgang Dichtl   +12 more
wiley   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source

Efficacy and Safety of Vonoprazan‐Based Dual Therapies With Different Antibiotics Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Four‐Arm, Randomized Controlled Trial

Helicobacter, Volume 31, Issue 3, May/June 2026.
ABSTRACT Background Vonoprazan‐based dual therapy has been proposed as a simplified strategy for Helicobacter pylori eradication, but head‐to‐head comparisons of different antibiotic partners are limited. We compared the efficacy, safety, and adherence of vonoprazan‐based dual regimens with those of bismuth‐containing quadruple therapy (BQT).
Jie Li, Deng‐Hua Li, Qi‐Qi Guo, Ju Zhang, Xiao‐Jing Zhu, Yu‐Hao Liu, Yan‐Peng Zhang, Min Chen, Yong‐Quan Shi   +8 more
wiley   +1 more source

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism. [PDF]

BMC Med, 2023
Yoon D, Jeong HE, Park S, You SC, Bang SM, Shin JY.   +5 more
europepmc   +1 more source

Efficacy and Safety of Dronedarone in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial

Journal of Cardiovascular Electrophysiology, Volume 37, Issue 5, Page 969-979, May 2026.
ABSTRACT Introduction Obesity represents a prevalent condition with multiple comorbidities, including atrial fibrillation (AF). Dronedarone, an antiarrhythmic drug (AAD), has demonstrated efficacy in patients with paroxysmal/persistent AF and cardiovascular (CV) risk factors.
Mate Vamos, Anna Vagvolgyi, David S. McKindley, Stefan H. Hohnloser   +3 more
wiley   +1 more source

How to Optimize the Administration of Low-Dose Non-vitamin K Antagonist Oral Anticoagulants in Everyday Practice? [PDF]

Anatol J Cardiol, 2022
Undas A.
europepmc   +1 more source

Methodological Concerns Regarding a Recent Meta‐Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Non‐Valvular Atrial Fibrillation

Clinical Cardiology, Volume 49, Issue 5, May 2026.
Omar Khalid Samir, Nikita Datta
wiley   +1 more source

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism [PDF]

, 2013

core   +1 more source

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment. [PDF]

Sci Rep, 2023
Lee HJ, Kim HK, Kim BS, Han KD, Park CS, Rhee TM, Park JB, Lee H, Kim YJ.   +8 more
europepmc   +1 more source

Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs

European Heart Journal, 2019
Semiha, Kurt, Orhan, Sumbul, Durdane, Aksoy   +2 more
openaire   +2 more sources